

Your success. Our priority.

Maintaining a global focus: a Q&A with David Dudding

David Dudding is the lead portfolio manager of the Global Focus strategy and co-manager of the European Select strategy Global equities have been exposed to topics that were very fashionable such as IT and healthcare. How have they impacted you?

We're not thematic investors, nor do we build portfolios from the top down. We prefer to assess individual companies on their own merits, looking for those that can compoundout growth consistently over a multi-year period. This naturally gives us exposure to certain secular trends – ecommerce, cloud computing, health care innovation, etc – many of which proved successful last year. These themes will not disappear in 2021 and many have arguably been accelerated.

Take cloud computing as an example. Corporate IT spend in 2020 was over US\$3.5 trillion, but only a small fraction of this went on cloud computing. But it is growing and its share of overall spend is only set to increase. This will benefit the dominant players in cloud infrastructure (a market that's not easy to disrupt). So while valuations may be stretched in some names, we still have conviction that we can find great companies with a growth runway that more than justifies the current valuation.

In view of a strong rebound in global economies in the wake of mass Covid vaccination programmes and a return of inflation, do you plan to shift the allocation of the portfolio towards more cyclical areas of the investment universe (such as consumption, financial services etc)?

Equity markets are pricing in an economic recovery at a rate faster than previously expected, something we also see reflected in the bond market. Improved economic sentiment is generally a boost for the average company that relies on economic growth to drive their own earnings growth and so in turn benefits value as a style. However, the post-Covid world is likely to be characterized by low economic growth, low interest rates and a build-up of debt. This is unlikely to benefit the average company. So while there will be companies for whom mass vaccination represents the potential end to a temporary headwind (eg, travel and consumer related industries), there are many others for whom this is short-term support. While we have no intention to materially shift the portfolio, we do have exposure to a range of companies that should benefit the reopening of economies. Our focus remains on high-quality companies that we believe can compound out returns over a multi-year time horizon. For portfolios that are heavily exposed to the US, how will this allocation change in the future? For example, will the big tech companies in Southeast Asia and China (such as Tencent, Alibaba and so on) become possible mediumor long-term targets?

Our exposure to the US is not driven by a top-down view of the US market. It just happens that we find a lot of great businesses in that part of the world. However, these are global businesses. What you also notice is that our exposure to emerging markets is the second largest. This is deliberate and comes from a mix of direct and indirect exposure. We have been adding selectively to emerging markets over the past few months, although not necessarily into big tech. Our focus has been more on the emerging platform businesses or financials, the latter being an industry that can be much less commoditised than its developed market counterpart.

The focus on such a broad investment universe requires a very high commitment in terms of analysis and research. How does this come about in terms of the size of the equity research team and how does it fit in with the strategy's relatively low costs?

We benefit from a very deep research capability and a strong collaborative culture at Columbia Threadneedle Investments. We have analysts across the globe, many of them portfolio managers in their own right, who could all potentially source an idea for us. This give us direct access to local market knowledge, which is something that is incredibly important to us. It also helps that they share a similar belief in what makes a company great. However, with that level of resource available, it's important to have a disciplined philosophy and process. In addition, we want to understand that we're investing in truly the best company in its industry on a global basis.

How important are the ESG aspects in company valuations and which of the E, S, and G are the most prevalent?

ESG is absolutely key to our process; it is one of the pillars that underpins our research framework and is inextricably linked to our focus on competitive advantage and industry structure. Just as we'd question a management team that allocates capital poorly, so we would question those that don't consider their ESG profile. While governance is clearly key for every investment that we make, we believe it important to focus on the material issues that impact a company when considering the E and the S elements. It is, in part, for this reason that we have developed our own internal RI rating system which focuses on industry materiality. This gives us conviction that we are asking the correct questions and focusing on the data points that matter for that particular company. In our view, this targeted and integrated approach should be supportive of stable, long-term outperformance.

To find out more visit **COLUMBIATHREADNEEDLE.COM**



Important Information: For use by Professional and/or Qualified Investors only (not to be used with or passed on to retail clients). This document is intended for informational purposes only and should not be considered representative of any particular investment. This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments, or to provide investment advice or services. Investing involves risk including the risk of loss of principal. Your capital is at risk. Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. The value of investments is not guaranteed, and therefore an investor may not get back the amount invested. International investing involves certain risks and volatility due to potential political, economic or currency fluctuations and different financial and accounting standards. The securities included herein are for illustrative purposes only, subject to change and should not be construed as a recommendation to buy or sell. Securities discussed may or may not prove profitable. The views expressed are as of the date given, may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments (Columbia Threadneedle) associates or affiliates. Actual investments or investment decisions made by Columbia Threadneedle and its affiliates, whether for its own account or on behalf of clients, may not necessarily reflect the views expressed. This information is not intended to provide investment advice and does not take into consideration individual investor circumstances. Investment decisions should always be made based on an investor's specific financial needs, objectives, goals, time horizon and risk tolerance. Asset classes described may not be suitable for all investors. Past performance does not guarantee future results, and no forecast should be considered a guarantee either. Information and opinions provided by third parties have been obtained from sou

In Australia: Issued by Threadneedle Investments Singapore (Pte.) Limited ["TIS"], ARBN 600 027 414. TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act and relies on Class Order 03/1102 in marketing and providing financial services to Australian wholesale clients as defined in Section 761G of the Corporations Act 2001. TIS is regulated in Singapore (Registration number: 201101559W) by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289), which differ from Australian laws.

In Singapore: Issued by Threadneedle Investments Singapore (Pte.) Limited, 3 Killiney Road, #07-07, Winsland House 1, Singapore 239519, which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289). Registration number: 201101559W. This advertisement has not been reviewed by the Monetary Authority of Singapore.

In Hong Kong: Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投資管理香港有限公司. Unit 3004, Two Exchange Square, 8 Connaught Place, Hong Kong, which is licensed by the Securities and Futures Commission ("SFC") to conduct Type 1 regulated activities (CE:AQA779). Registered in Hong Kong under the the Companies Ordinance (Chapter 622), No. 1173058.

In EEA: Threadneedle Management Luxembourg S.A. Registered with the Registre de Commerce et des Societes (Luxembourg), Registered No. B 110242 44, rue de la Vallée, L-2661 Luxembourg, Grand Duchy of Luxembourg.

In UK: Issued by Threadneedle Asset Management Limited. Registered in England and Wales, Registered No. 573204, Cannon Place, 78 Cannon Street, London EC4N 6AG, United Kingdom. Authorised and regulated in the UK by the Financial Conduct Authority.

In Switzerland: Issued by Threadneedle Portfolio Services AG, Registered address: Claridenstrasse 41, 8002 Zurich, Switzerland.

This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA). For Distributors: This document is intended to provide distributors' with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it. Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies. columbiathreadneedle.com